Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.

@article{GomesdaSilva2013ImpactOA,
  title={Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.},
  author={L{\'i}gia C Gomes-da-Silva and Jos{\'e} S. Ramalho and Maria C Pedroso de Lima and S{\'e}rgio Sim{\~o}es and Jo{\~a}o Nuno Moreira},
  journal={European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V},
  year={2013},
  volume={85 3 Pt A},
  pages={
          356-64
        }
}
  • L. C. Gomes-da-Silva, J. Ramalho, J. Moreira
  • Published 1 November 2013
  • Biology, Chemistry
  • European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer
TLDR
The efficacy, specificity, and delivery of si RNAs are comprehensively discussed in this review to direct further studies toward using siRNAs and their nanoscale-delivery systems in PCa therapy and perhaps other cancer types.
Anti-angiogenic Therapy by Targeting the Tumor Vasculature with Liposomes
TLDR
This article reviews the various tumor endothelial targeting nano drug delivery systems that involve the use of cationic lipids, peptides, antibodies sugar chains and the mechanisms responsible for how endothelial cells affect a tumor microenvironment for nanoparticle penetration in tumor tissues are reviewed.
AS1411-functionalized delivery nanosystems for targeted cancer therapy
TLDR
The high affinity and specificity of AS1411 towards NCL make it a suitable targeting tool, which can be used for the functionalization of therapeutic payloaddelivery nanosystems to selectively target tumor cells.
Aptamer-Assisted Delivery of Nucleotides with Tumor-Suppressing Properties for Targeted Cancer Therapies
TLDR
The light is shed on the application of aptamers for the delivery of nucleotides such as MicroRNAs, short or small interfering RNAs, and short hairpin RNA or small hairpin RNAs that harbor tumor suppression properties in various kinds of malignancies.
Targeted Delivery of siRNA Therapeutics to Malignant Tumors
TLDR
The major categories of ligand-targeted siRNA therapeutics for tumors are discussed, as well as the different strategies to identify new ligands.
Nucleolin Overexpression Predicts Patient Prognosis While Providing a Framework for Targeted Therapeutic Intervention in Lung Cancer
TLDR
Characterizing nucleolin expression in patient-derived pulmonary carcinomas and further validating nucleolin as a novel target to mediate successful therapeutic interventions against human lung cancers suggested nucleolin overexpression as a poor prognosis predictor and thus a target for therapeutic intervention in lung cancer.
...
...

References

SHOWING 1-10 OF 41 REFERENCES
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.
TLDR
Preclinical development of chemically modified siRNA targeting the essential cell-cycle proteins polo-like kinase 1 (PLK1) and kinesin spindle protein (KSP) in mice is described, suggesting a new methodology for targeting other key genes in cancer development with siRNA-based therapeutics.
Rational combinations of siRNAs targeting Plk1 with breast cancer drugs
TLDR
Treatment of breast cancer cells with siRNAs targeting Plk1 improved the sensitivity toward paclitaxel and Herceptin in a synergistic manner and very low concentrations across a wide range of clinically relevant concentrations were sufficient to induce an antiproliferative effect.
Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA
TLDR
The feasibility of liposomal-mediated delivery of COx-2-specific siRNA to downregulate COX-2 in cancer cells, and multi-modality imaging of the delivery of specific siRNA in tumors are demonstrated.
Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents.
TLDR
It is demonstrated that the combination of a survivin-directed silencing strategy with chemotherapeutic agents constitutes a valuable approach for cancer treatment.
Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
TLDR
The design and synthesis of novel cationic lipids that are more fusogenic and the use of internalizing targeting ligands have contributed to the emergence of novel lipid-based nanoparticles with remarkable transfection efficiency.
Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells.
TLDR
PLK1 function appears to be essential for centrosome-mediated microtubule events and, consequently, for spindle assembly in neoplastic cells at very low doses of siRNAs targeted to PLK1.
Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
TLDR
The study showed that knockdown of PLK1 by shRNA might be the potential therapeutic approach against human colorectal carcinoma.
[Influence of silencing Polo-like kinase 1 on migration and invasion of colorectal cancer cells].
TLDR
PLK1 silencing by siRNA may inhibit the migration and invasiveness of colorectal cancer cells, suggesting that PLK1 might play an important role in the infiltration and metastasis of colorean cancer.
pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1.
TLDR
P pH-responsive ternary complexes were developed for the delivery of siRNA and used to deliver siRNA against polo-like kinase 1 (plk1), a gene upregulated in many cancers and responsible for cell cycle progression, to ovarian cancer cell lines.
...
...